Posttraumatic Stress Disorder (PTSD) is a condition that can develop after an individual is exposed to a traumatic event, such as in combat, natural disasters, terrorist attacks, car wrecks, being mugged, or domestic violence. Evidence-based treatments are available (see the APA Practice Guidelines, for example), but no treatment works for everyone and a substantial number of people develop a chronic form which is refractory to many treatments (data from National Center for PTSD and Breslau et al., 2001). A wider set of therapeutic options appears necessary.

Trigeminal Nerve Stimulation (TNS) is a new investigational treatment for disorders of the brain, including treatment-resistant epilepsy and major depression and now PTSD. Clinical trials are now underway at UCLA in Los Angeles. TNS for neurological and psychiatric disorders was invented by Drs. Christopher M. DeGiorgio, Ian A. Cook, and their teams at UCLA; the intellectual property is owned by the University of California and has been licensed to a neuromodulation company, NeuroSigma, Inc. for further translational development so these treatments can be made available to patients.

For a video perspective on TNS, you can view this video on YouTube.

For comments on a study of medications for PTSD, please see this clip from MSNBC